Reckitt Benckiser Group plc RKT.L
Composite 62/100; the shares have moved about 26% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 43/100 — a slight mark against it.
Income ranks 85/100 — a strong point in its favour. Quality ranks 77/100 — a strong point in its favour. Valuation ranks 66/100 — a moderate point in its favour.
Momentum ranks 43/100 — a slight mark against it. Balance-sheet strength ranks 48/100 — a slight mark against it.
What the company does Reckitt Benckiser Group plc (RKT.L) is a UK-based multinational consumer health and hygiene company with brands like Dettol, Durex, Lysol, Enfamil, and Mucinex. It operates across health, hygiene, nutrition, and infant formula segments, serving global markets.
Key financials RKT posts strong profitability metrics: ROE 44.2%, ROA 8.5%, ROCE 36.3%, gross margin 60.8%, and net margin 22.4%. However, revenue declined -2.6% and EPS fell -13.2%. Debt/equity is 1.80 with net debt/EBITDA at 2.61, and dividend yield is 4.1% with a payout ratio of 48.6%.
Stock health Momentum is mixed: +16.30% over 3m but -12.99% over 6m and -8.21% over 12m. RSI(14) is 70.10, indicating overbought conditions. Sideravia scores quality 82.5 and income 89.7, offset by growth 30.5 and momentum 40.9.
Price vs fair value The stock trades at a PREMIUM of 18.90% to our fair-value estimate and a discount of 14.74% to the analyst 12-month target. - Recent price strength aligns with H1 2026 earnings call highlights (GuruFocus.com, MarketBeat). - Price hikes to offset Iran war-related cost pressures may support margins (The Wall Street Journal, PA Media). - FTSE 100 strength and defensive sector positioning may be lifting sentiment (Proactive).
Looking forward Forward P/E of 15.95 suggests moderate valuation, but growth remains weak. Execution on pricing power and cost management will be key to closing the valuation gap.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.